应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
02496 友芝友生物-B
休市中 08-23 09:01:16
6.420
+0.000
0.00%
最高
6.420
最低
6.420
成交量
0.00
今开
6.420
昨收
6.420
日振幅
0.00%
总市值
12.45亿
流通市值
7.16亿
总股本
1.94亿
成交额
0.00
换手率
0.00%
流通股本
1.11亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
友芝友生物-B(02496)股价下跌8.023%,现价港币$6.42
阿斯达克财经 · 08-22
友芝友生物-B(02496)股价下跌8.023%,现价港币$6.42
友芝友生物-B(02496.HK)拟8月29日举行董事会会议审批中期业绩
格隆汇 · 08-19
友芝友生物-B(02496.HK)拟8月29日举行董事会会议审批中期业绩
【友芝友生物-B(02496.HK):Dai Weiguo辞任独立非执行董事】智通财经APP讯,友芝友生物-B(02496.
智通财经 · 07-30
【友芝友生物-B(02496.HK):Dai Weiguo辞任独立非执行董事】智通财经APP讯,友芝友生物-B(02496.
友芝友生物-B(02496):Dai Weiguo辞任独立非执行董事
智通财经 · 07-30
友芝友生物-B(02496):Dai Weiguo辞任独立非执行董事
友芝友生物M701:恶性腹水治疗新突破,临床试验显示生存期显著延长
和讯网 · 06-05
友芝友生物M701:恶性腹水治疗新突破,临床试验显示生存期显著延长
友芝友生物-B建议采纳2024年H股购股权计划
新浪港股 · 05-30
友芝友生物-B建议采纳2024年H股购股权计划
友芝友生物-B(02496)建议采纳2024年H股购股权计划
智通财经 · 05-29
友芝友生物-B(02496)建议采纳2024年H股购股权计划
【友芝友生物-B(02496.HK)建议采纳2024年H股购股权计划】智通财经APP讯,友芝友生物-B(02496.HK)发布公告,于2024年5月29日,董事会已决议根据上市规则第17章建议采纳2024年H股购股权计划,以供股东于公司将于2024年6月27日(星期四)举行的股东周年大会上批准。
智通财经 · 05-29
【友芝友生物-B(02496.HK)建议采纳2024年H股购股权计划】智通财经APP讯,友芝友生物-B(02496.HK)发布公告,于2024年5月29日,董事会已决议根据上市规则第17章建议采纳2024年H股购股权计划,以供股东于公司将于2024年6月27日(星期四)举行的股东周年大会上批准。
友芝友生物-B(02496):M701恶性腹水II期研究数据在2024年ASCO会议上公布
智通财经 · 05-24
友芝友生物-B(02496):M701恶性腹水II期研究数据在2024年ASCO会议上公布
【友芝友生物-B(02496.HK):M701恶性腹水II期研究数据在2024年ASCO会议上公布】智通财经APP讯,友芝友生物-B(02496.
智通财经 · 05-24
【友芝友生物-B(02496.HK):M701恶性腹水II期研究数据在2024年ASCO会议上公布】智通财经APP讯,友芝友生物-B(02496.
友芝友生物(02496.HK)于美国临床肿瘤学会公布M701 II期临床研究中期分析数据
阿斯达克财经 · 05-24
友芝友生物(02496.HK)于美国临床肿瘤学会公布M701 II期临床研究中期分析数据
友芝友生物-B(02496):柳丹辞任非执行董事
智通财经网 · 04-30
友芝友生物-B(02496):柳丹辞任非执行董事
【友芝友生物-B(02496.HK):柳丹辞任非执行董事】智通财经APP讯,友芝友生物-B(02496.HK)发布公告,柳丹,因个人工作变动的原因,已提交辞呈辞任非执行董事。
智通财经 · 04-30
【友芝友生物-B(02496.HK):柳丹辞任非执行董事】智通财经APP讯,友芝友生物-B(02496.HK)发布公告,柳丹,因个人工作变动的原因,已提交辞呈辞任非执行董事。
《公司业绩》友芝友生物(02496.HK)全年亏损扩至1.92亿人民币
阿斯达克财经 · 03-31
《公司业绩》友芝友生物(02496.HK)全年亏损扩至1.92亿人民币
友芝友生物-B(02496)发布年度业绩 股东应占亏损1.92亿元 同比扩大1.5%
智通财经 · 03-28
友芝友生物-B(02496)发布年度业绩 股东应占亏损1.92亿元 同比扩大1.5%
【友芝友生物-B(02496.HK):双特异性抗体M701恶性腹水III期临床试验完成首例患者入组】智通财经APP讯,友芝友生物-B(02496.
智通财经 · 03-27
【友芝友生物-B(02496.HK):双特异性抗体M701恶性腹水III期临床试验完成首例患者入组】智通财经APP讯,友芝友生物-B(02496.
友芝友生物-B(02496.HK)双特异性抗体M701恶性胸水二期临床完成首例患者入组
阿斯达克财经 · 03-27
友芝友生物-B(02496.HK)双特异性抗体M701恶性胸水二期临床完成首例患者入组
友芝友生物-B(02496):双特异性抗体M701恶性胸水II期临床试验完成首例患者入组
智通财经 · 03-26
友芝友生物-B(02496):双特异性抗体M701恶性胸水II期临床试验完成首例患者入组
【友芝友生物-B(02496.HK):双特异性抗体M701恶性胸水II期临床试验完成首例患者入组】智通财经APP讯,友芝友生物-B(02496.
智通财经 · 03-26
【友芝友生物-B(02496.HK):双特异性抗体M701恶性胸水II期临床试验完成首例患者入组】智通财经APP讯,友芝友生物-B(02496.
友芝友生物-B(02496.HK)拟3月28日举行董事会会议批准全年业绩
格隆汇资讯 · 03-15
友芝友生物-B(02496.HK)拟3月28日举行董事会会议批准全年业绩
公司概况
公司名称:
友芝友生物-B
所属市场:
SEHK
上市日期:
--
主营业务:
武汉友芝友生物制药股份有限公司是一家主要从事药品研发、生产和销售的中国公司。该公司主要从事双特异性抗体药物的研发及产业化。该公司主要产品包括抗程序性死亡受体1和抗分化簇3、抗分化簇19和抗分化簇3、抗CDX和分化簇3。该公司的药品主要应用于肿瘤、免疫、炎症、心血管、感染等重大疾病领域。
发行价格:
--
{"stockData":{"symbol":"02496","market":"HK","secType":"STK","nameCN":"友芝友生物-B","latestPrice":6.42,"timestamp":1724374876437,"preClose":6.42,"halted":0,"volume":0,"delay":0,"floatShares":111468814,"shares":193849200,"eps":-1.134838,"marketStatus":"休市中","marketStatusCode":7,"change":0,"latestTime":"08-23 09:01:16","open":6.42,"high":6.42,"low":6.42,"amount":0,"amplitude":0,"askPrice":6.5,"askSize":800,"bidPrice":5.5,"bidSize":400,"shortable":0,"etf":0,"ttmEps":-1.1348379688608565,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1724635800000},"adr":0,"listingDate":1695571200000,"adjPreClose":6.42,"openAndCloseTimeList":[[1724376600000,1724385600000],[1724389200000,1724400000000]],"volumeRatio":0,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02496/wiki","defaultTab":"wiki","newsList":[{"id":"2461339561","title":"友芝友生物-B(02496)股价下跌8.023%,现价港币$6.42","url":"https://stock-news.laohu8.com/highlight/detail?id=2461339561","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461339561?lang=zh_cn&edition=full","pubTime":"2024-08-22 10:45","pubTimestamp":1724294700,"startTime":"0","endTime":"0","summary":"[下跌股]友芝友生物-B(02496) 股价在上午10:45比前收市价下跌8.023%,现股价为港币$6.42。至目前为止,今日最高价为$6.42,而最低价为$6.42。总成交量为400股,总成交金额为港币$2568。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205152747204_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205152747204_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD240822793/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02496","BK1161"],"gpt_icon":0},{"id":"2460651088","title":"友芝友生物-B(02496.HK)拟8月29日举行董事会会议审批中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2460651088","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460651088?lang=zh_cn&edition=full","pubTime":"2024-08-19 16:43","pubTimestamp":1724057034,"startTime":"0","endTime":"0","summary":"格隆汇8月19日丨友芝友生物-B(02496.HK)公告,谨定于2024年8月29日(星期四)举行董事会会议,藉以(其中包括)考虑及批准公司及其附属公司截至2024年6月30日止6个月的中期业绩及其发布,以及处理其他事项。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240819164354a1d4f3c5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240819164354a1d4f3c5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02496","BK1161"],"gpt_icon":0},{"id":"2455981819","title":"【友芝友生物-B(02496.HK):Dai Weiguo辞任独立非执行董事】智通财经APP讯,友芝友生物-B(02496.","url":"https://stock-news.laohu8.com/highlight/detail?id=2455981819","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2455981819?lang=zh_cn&edition=full","pubTime":"2024-07-30 18:29","pubTimestamp":1722335395,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MKR.USD.HKCC","BK1161","02496"],"gpt_icon":0},{"id":"2455023989","title":"友芝友生物-B(02496):Dai Weiguo辞任独立非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2455023989","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2455023989?lang=zh_cn&edition=full","pubTime":"2024-07-30 18:29","pubTimestamp":1722335395,"startTime":"0","endTime":"0","summary":"智通财经APP讯,友芝友生物-B(02496)发布公告,Dai Weiguo提交辞呈辞任独立非执行董事及董事会提名委员会成员,以投入更多时间于其他个人事务。根据《中华人民共和国公司法》等相关法律法规和公司章程的规定,Dai博士的辞任自2024年7月30日起生效。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1157522.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02496","BK1161"],"gpt_icon":0},{"id":"2441103242","title":"友芝友生物M701:恶性腹水治疗新突破,临床试验显示生存期显著延长","url":"https://stock-news.laohu8.com/highlight/detail?id=2441103242","media":"和讯网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2441103242?lang=zh_cn&edition=full","pubTime":"2024-06-05 14:35","pubTimestamp":1717569354,"startTime":"0","endTime":"0","summary":"友芝友生物的M701,一种双靶向双抗药物,已在中国开展多项临床试验,包括针对恶性腹水的关键III期试验。M701的临床试验结果显示,试验组的无穿刺生存时间显著长于对照组,且在多个癌种类型中均显示出获益趋势。此外,M701治疗的受试者生存期有延长趋势,6个月生存率也有所提高。M701的研发不仅为恶性胸腹水患者提供了新的治疗选择,也预示着肿瘤治疗领域的新突破,有望为医疗保健系统带来积极影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406051437389f1bba2c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406051437389f1bba2c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02496","03347","BK1141","BK1583","BK1576","BK1161"],"gpt_icon":0},{"id":"2439637292","title":"友芝友生物-B建议采纳2024年H股购股权计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2439637292","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2439637292?lang=zh_cn&edition=full","pubTime":"2024-05-30 09:25","pubTimestamp":1717032354,"startTime":"0","endTime":"0","summary":"友芝友生物-B(02496)发布公告,于2024年5月29日,董事会已决议根据上市规则第17章建议采纳2024年H股购股权计划,以供股东于公司将于2024年6月27日(星期四)举行的股东周年大会上批准。\n 2024年H股购股权计划的目的为:认可及肯定合资格参与者已经或可能已经或可能对集团作出的贡献;提升合资格参与者的积极性及忠诚度,从而促进企业的长期发展及提高股东价值;及建立员工、股东与公司利益共享、风险共担的健全机制。\n\n股市回暖,抄底炒股先开户!智能定投、条件单、个股雷达……送给你>>\n\n\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-05-30/doc-inawyfsn1726987.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-05-30/doc-inawyfsn1726987.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_sina","symbols":["02496","BK1161"],"gpt_icon":0},{"id":"2439527892","title":"友芝友生物-B(02496)建议采纳2024年H股购股权计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2439527892","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2439527892?lang=zh_cn&edition=full","pubTime":"2024-05-29 21:34","pubTimestamp":1716989658,"startTime":"0","endTime":"0","summary":"智通财经APP讯,友芝友生物-B(02496)发布公告,于2024年5月29日,董事会已决议根据上市规则第17章建议采纳2024年H股购股权计划,以供股东于公司将于2024年6月27日(星期四)举行的股东周年大会上批准。2024年H股购股权计划的目的为:认可及肯定合资格参与者已经或可能已经或可能对集团作出的贡献;提升合资格参与者的积极性及忠诚度,从而促进企业的长期发展及提高股东价值;及建立员工、股东与公司利益共享、风险共担的健全机制。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1128008.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02496"],"gpt_icon":0},{"id":"2439273295","title":"【友芝友生物-B(02496.HK)建议采纳2024年H股购股权计划】智通财经APP讯,友芝友生物-B(02496.HK)发布公告,于2024年5月29日,董事会已决议根据上市规则第17章建议采纳2024年H股购股权计划,以供股东于公司将于2024年6月27日(星期四)举行的股东周年大会上批准。","url":"https://stock-news.laohu8.com/highlight/detail?id=2439273295","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2439273295?lang=zh_cn&edition=full","pubTime":"2024-05-29 21:34","pubTimestamp":1716989658,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02496"],"gpt_icon":0},{"id":"2437707818","title":"友芝友生物-B(02496):M701恶性腹水II期研究数据在2024年ASCO会议上公布","url":"https://stock-news.laohu8.com/highlight/detail?id=2437707818","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2437707818?lang=zh_cn&edition=full","pubTime":"2024-05-24 16:33","pubTimestamp":1716539594,"startTime":"0","endTime":"0","summary":"试验组受试者接受腹腔穿刺引流和腹腔灌注M701药物,药物使用剂量和频次为在第1天灌注50μgM701,在第4、11和18天分别灌注400μg。后续每2周腹腔灌注1次M701,且不再引流腹水。结论:上皮性实体肿瘤伴有恶性腹水的患者在进行全身系统性治疗的同时,对腹腔灌注M701耐受良好,且未展现高于仅进行腹腔穿刺引流的患者的风险。这些结果充满希望,且能有力地支持M701作为治疗恶性腹水的新型药物进入关键研究。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1125718.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02496"],"gpt_icon":0},{"id":"2437707590","title":"【友芝友生物-B(02496.HK):M701恶性腹水II期研究数据在2024年ASCO会议上公布】智通财经APP讯,友芝友生物-B(02496.","url":"https://stock-news.laohu8.com/highlight/detail?id=2437707590","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2437707590?lang=zh_cn&edition=full","pubTime":"2024-05-24 16:33","pubTimestamp":1716539594,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","CD3.AU","02496"],"gpt_icon":0},{"id":"2437470066","title":"友芝友生物(02496.HK)于美国临床肿瘤学会公布M701 II期临床研究中期分析数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2437470066","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2437470066?lang=zh_cn&edition=full","pubTime":"2024-05-24 16:33","pubTimestamp":1716539580,"startTime":"0","endTime":"0","summary":"结论是上皮性实体肿瘤伴有恶性腹水的患者在进行全身系统性治疗的同时,对腹腔灌注M701耐受良好,且未展现高于仅进行腹腔穿刺引流的患者的风险。同时,经过M701治疗的患者展现出了延长的无穿刺生存时间和总生存时间。这些结果充满希望,且能有力地支持M701作为治疗恶性腹水的新型药物进入关键研究。","market":"other","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20230918101532905_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20230918101532905_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1352016/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","02496"],"gpt_icon":0},{"id":"2431925193","title":"友芝友生物-B(02496):柳丹辞任非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2431925193","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2431925193?lang=zh_cn&edition=full","pubTime":"2024-04-30 17:36","pubTimestamp":1714469780,"startTime":"0","endTime":"0","summary":"智通财经APP讯,友芝友生物-B(02496)发布公告,柳丹,因个人工作变动的原因,已提交辞呈辞任非执行董事。根据《中华人民共和国公司法》等相关法律法规和公司章程的规定,柳丹的辞任自2024年4月30日起生效。更多港股重磅资讯,下载智通财经app更多港股及海外理财资讯,请点击www.zhitongcaijing.com(搜索“智通财经”);欲加入智通港股投资群,请加智通客服微信(ztcjkf)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1116305.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1161","02496"],"gpt_icon":0},{"id":"2431392609","title":"【友芝友生物-B(02496.HK):柳丹辞任非执行董事】智通财经APP讯,友芝友生物-B(02496.HK)发布公告,柳丹,因个人工作变动的原因,已提交辞呈辞任非执行董事。","url":"https://stock-news.laohu8.com/highlight/detail?id=2431392609","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2431392609?lang=zh_cn&edition=full","pubTime":"2024-04-30 17:36","pubTimestamp":1714469780,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02496","BK1161"],"gpt_icon":0},{"id":"2423652221","title":"《公司业绩》友芝友生物(02496.HK)全年亏损扩至1.92亿人民币","url":"https://stock-news.laohu8.com/highlight/detail?id=2423652221","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2423652221?lang=zh_cn&edition=full","pubTime":"2024-03-31 20:57","pubTimestamp":1711889820,"startTime":"0","endTime":"0","summary":"友芝友生物-B(02496.HK) 公布2023年止年度业绩,其他收入录得1,301万人民币(下同)。亏损由上年度1.89亿元,扩至1.92亿元,每股亏损1.04元。不派末期息。(de/d)(港股报价延迟最少十五分钟。)AASTOCKS新闻","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20230913084201322_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20230913084201322_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1338791/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02496","BK1161"],"gpt_icon":0},{"id":"2422319150","title":"友芝友生物-B(02496)发布年度业绩 股东应占亏损1.92亿元 同比扩大1.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2422319150","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2422319150?lang=zh_cn&edition=full","pubTime":"2024-03-28 21:22","pubTimestamp":1711632135,"startTime":"0","endTime":"0","summary":"智通财经APP讯,友芝友生物-B(02496)发布截至2023年12月31日止年度的年度业绩,该集团期内取得其他收入1301.4万元(人民币,下同),同比增加408.36%;股东应占亏损1.92亿元,同比扩大1.5%;每股基本亏损1.04元。公告称,集团的其他收入由同期的260万元增加至报告期的1300万元,主要由于政府补助增加970万元,因为集团从地方政府获得补助,作为集团候选药物研发的奖励及集团于2023年9月成功上市获得地方政府奖励。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032821230287c0de07&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032821230287c0de07&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02496"],"gpt_icon":0},{"id":"2422913869","title":"【友芝友生物-B(02496.HK):双特异性抗体M701恶性腹水III期临床试验完成首例患者入组】智通财经APP讯,友芝友生物-B(02496.","url":"https://stock-news.laohu8.com/highlight/detail?id=2422913869","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2422913869?lang=zh_cn&edition=full","pubTime":"2024-03-27 20:49","pubTimestamp":1711543796,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4134","03347","BK1161","02496","BK1141","III","CD3.AU","BK1583","BK1576"],"gpt_icon":0},{"id":"2422360904","title":"友芝友生物-B(02496.HK)双特异性抗体M701恶性胸水二期临床完成首例患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2422360904","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2422360904?lang=zh_cn&edition=full","pubTime":"2024-03-27 09:20","pubTimestamp":1711502400,"startTime":"0","endTime":"0","summary":"友芝友生物-B(02496.HK) 公布,公司自主研发的上皮细胞黏附分子(EpCAM)和分化簇3(CD3)双靶向的在研双特异性抗体(BsAb)药物M701于近日完成恶性胸水二期临床研究首例患者入组。恶性胸水研究的目的是研究胸腔灌注M701对比胸腔穿刺引流和╱或胸腔化疗在非小细胞肺癌导致的恶性胸水患者中的有效性和安全性。公司指,恶性胸水是一种常见于晚期肺癌和乳腺癌等癌症患者的并发症,其成因是肿瘤细胞侵袭组织和引起负性因子释放等导致内皮细胞异常和渗出液增多、以及肿瘤细胞堵塞淋巴管导致淋巴液积聚。(ek/u)(港股报价延迟最少十五分钟。)AASTOCKS新闻","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20230918101531874_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20230918101531874_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1337456/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02496","BK1161"],"gpt_icon":0},{"id":"2422610732","title":"友芝友生物-B(02496):双特异性抗体M701恶性胸水II期临床试验完成首例患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2422610732","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2422610732?lang=zh_cn&edition=full","pubTime":"2024-03-26 23:19","pubTimestamp":1711466362,"startTime":"0","endTime":"0","summary":"智通财经APP讯,友芝友生物-B 发布公告,公司自主研发的上皮细胞黏附分子和分化簇3双靶向的在研双特异性抗体药物M701于近日完成恶性胸水II期临床研究首例患者入组。因此胸腔灌注M701可激活免疫细胞靶向清除和抑制胸腔中肿瘤细胞,从而达到抑制胸水的效果。在公司开展的恶性胸水Ib期临床研究中,胸腔灌注M701展现出良好的安全性和有效性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1092976.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02496","BK1583","BK1161","03347","BK1576","BK1141"],"gpt_icon":0},{"id":"2422296610","title":"【友芝友生物-B(02496.HK):双特异性抗体M701恶性胸水II期临床试验完成首例患者入组】智通财经APP讯,友芝友生物-B(02496.","url":"https://stock-news.laohu8.com/highlight/detail?id=2422296610","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2422296610?lang=zh_cn&edition=full","pubTime":"2024-03-26 23:19","pubTimestamp":1711466362,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1583","BK1161","BK1141","02496","CD3.AU","03347","BK1576"],"gpt_icon":0},{"id":"2419427759","title":"友芝友生物-B(02496.HK)拟3月28日举行董事会会议批准全年业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2419427759","media":"格隆汇资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2419427759?lang=zh_cn&edition=full","pubTime":"2024-03-15 16:50","pubTimestamp":1710492640,"startTime":"0","endTime":"0","summary":"格隆汇3月15日丨友芝友生物-B(02496.HK)公布,董事会通告谨定于2024年3月28日(星期四)举行董事会会议,藉以(其中包括)考虑及批准公司及其附属公司截至2023年12月31日止年度的全年业绩及其发布,以及处理其他事项。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403151653038785ed1d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403151653038785ed1d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02496"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.yzybio.com","stockEarnings":[{"period":"1week","weight":-0.1181},{"period":"1month","weight":-0.1406},{"period":"3month","weight":-0.1383},{"period":"6month","weight":-0.2578},{"period":"1year","weight":-0.5988},{"period":"ytd","weight":-0.2787}],"compareEarnings":[{"period":"1week","weight":0.0104},{"period":"1month","weight":0.0174},{"period":"3month","weight":-0.0536},{"period":"6month","weight":0.053},{"period":"1year","weight":-0.0329},{"period":"ytd","weight":0.0331}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"武汉友芝友生物制药股份有限公司是一家主要从事药品研发、生产和销售的中国公司。该公司主要从事双特异性抗体药物的研发及产业化。该公司主要产品包括抗程序性死亡受体1和抗分化簇3、抗分化簇19和抗分化簇3、抗CDX和分化簇3。该公司的药品主要应用于肿瘤、免疫、炎症、心血管、感染等重大疾病领域。","exchange":"SEHK","name":"友芝友生物-B","nameEN":"YZYBIO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"友芝友生物-B(02496)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供友芝友生物-B(02496)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"友芝友生物-B,02496,友芝友生物-B股票,友芝友生物-B股票老虎,友芝友生物-B股票老虎国际,友芝友生物-B行情,友芝友生物-B股票行情,友芝友生物-B股价,友芝友生物-B股市,友芝友生物-B股票价格,友芝友生物-B股票交易,友芝友生物-B股票购买,友芝友生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"友芝友生物-B(02496)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供友芝友生物-B(02496)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}